Pyoderma gangrenosum - Пиодерма Гангреносум
Пиодерма Гангреносум (Pyoderma gangrenosum) је ретка, инфламаторна болест коже где болне пустуле или чворови постају чиреви који прогресивно расту. пиодерма гангреносум (pyoderma gangrenosum) није заразна. Третмани могу укључивати кортикостероиде, циклоспорин или различита моноклонска антитела. Иако може утицати на људе било ког узраста, углавном погађа људе у 40-им и 50-им годинама.
☆ У резултатима Стифтунг Варентест-а за 2022. из Немачке, задовољство потрошача МоделДерм-ом је само нешто ниже него са плаћеним телемедицинским консултацијама.
На нози особе са улцерозним колитисом.
References
Pyoderma gangrenosum је ретко стање коже које изазива болне чиреве са црвеним или љубичастим ивицама. Класификован је као инфламаторна болест и део је групе која се зове неутрофилне дерматозе. Узрок pyoderma gangrenosum је сложен, укључује проблеме и са урођеним и са адаптивним имунитетом код људи који су генетски склони. Недавно су се истраживачи фокусирали на фоликул длаке као потенцијалну почетну тачку болести.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum је ретко стање коже које изазива изузетно болне чиреве. Иако не разумемо у потпуности његов узрок, знамо да укључује повећану активност одређених имуних ћелија. Лечење болести и даље није лако. Имамо разне лекове који потискују имуни систем или модификују његову активност. Поред тога, фокусирамо се и на лечење рана и управљање болом. Кортикостероиди и циклоспорин су често први избор за лечење, али у последње време постоји више истраживања о коришћењу биолошких терапија као што су инхибитори ТНФ-α. Ови биолошки лекови су све пожељнији, посебно код пацијената са другим инфламаторним стањима, а користе се и раније у процесу болести.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
